Verastem
Verastem Oncology RAF/MEKFocus

Research

Verastem Oncology’s portfolio consists of potential cancer therapies that target critical signaling pathways in tumors. These signaling pathways are abnormal in cancer and promote cancer cell survival and tumor growth.

Our programs target rapidly accelerated fibrosarcoma/ mitogen‑activated protein kinase (RAF/MEK) and focal adhesion kinase (FAK). Preclinical research has shown that these targets are important for both cancer cell survival and the tumor microenvironment that supports the cancer cells.